⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398604 | 1.00 | — | — | |
| SCHEMBL233383 | 0.78 | — | — | |
| SCHEMBL578361 | 0.78 | — | — | |
| SCHEMBL12472408 | 0.76 | — | — | |
| SCHEMBL3862530 | 0.76 | — | — | |
| SCHEMBL1262920 | 0.76 | — | — | |
| SCHEMBL13163259 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL17727573 | 0.74 | — | — | |
| SCHEMBL61372 | 0.74 | — | — | |
| SCHEMBL5557115 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110691788-B | Long acting GIP peptide analogues | 哥本哈根大学 | 2024-05-31 | — | — | CN | claimed |
| CN-117881415-A | Treatment of obesity and obesity-related disorders | 安泰博医药 | 2024-04-12 | — | — | CN | claimed |
| CN-114761420-A | Optimized GIP peptide analogs | 安泰博医药 | 2022-07-15 | — | — | CN | claimed |
| CN-113366014-A | Modified GIP peptide analogs | 安泰博医药 | 2021-09-07 | — | — | CN | claimed |
| CN-110691788-A | Long-acting GIP peptide analogs | 哥本哈根大学 | 2020-01-14 | — | — | CN | claimed |
| CN-110691788-B | Long acting GIP peptide analogues | 哥本哈根大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117881415-A | Treatment of obesity and obesity-related disorders | 安泰博医药 | 2024-04-12 | — | — | CN | disclosed |
| CN-117500510-A | Deoxynucleoside prodrugs for treating mitochondrial diseases caused by unbalanced nucleotide pools | 周格尼克斯公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117120060-A | Aqueous solutions containing purines and pyrimidines and use thereof | 周格尼克斯-莫迪斯公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116731098-A | Nucleoside phosphoramidate prodrugs | 吉利德科学公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116731099-A | Nucleoside phosphoramidate prodrugs | 吉利德科学公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-112384228-A | Prodrugs of deoxynucleosides for treating diseases caused by unbalanced nucleotide pools | 莫迪斯治疗公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-111848711-A | 2' -chloronucleoside analogs for HCV infection | 埃迪尼克斯医药有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-110691788-A | Long-acting GIP peptide analogs | 哥本哈根大学 | 2020-01-14 | — | — | CN | disclosed |
| CN-110603252-A | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders | 艾其林医药公司 | 2019-12-20 | — | — | CN | disclosed |
| CN-110573522-A | SIRP alpha-41 BBL fusion protein and method of use thereof | 卡尔医学有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-2057147-A1 | PYRIMIDINE DERIVATIVES | Astra Zeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |